At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 421 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes
In Brief
A Phase 3 clinical trial evaluating Placebo and Fasiglifam for Diabetes Mellitus, Type 2. Completed, enrolled 421 participants across 95 sites in 8 countries.
Detailed Summary
The purpose of this study is to determine the efficacy and safety of TAK-875 (fasiglifam), once daily (QD), in participants with type 2 diabetes mellitus (T2DM).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesArgentina, Bulgaria, Guatemala, Hungary, Mexico, Slovakia, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 2011
Enrollment StartNov 2011
Primary CompletionJul 2013
TodayJul 2026
First PostedOct 20, 2011
Enrollment StartNov 1, 2011
Primary CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 14.7 years ago
Interventions
Placebodrug
Fasiglifam placebo-matching tablets
Fasiglifamdrug
Fasiglifam tablets